Research programme: antibody-drug conjugates - PDL BioPharma

Drug Profile

Research programme: antibody-drug conjugates - PDL BioPharma

Alternative Names: Anti-TMEFF2 ADC; Anti-TMEFF2-MMAE conjugate; Anti-TMEFF2-monomethyl auristatin E conjugate; Anti-tomoregulin ADC; Anti-tomoregulin-MMAE conjugate; Anti-tomoregulin-monomethyl auristatin E conjugate; Humanised anti-TMEFF2-auristatin E conjugated mAb; Humanised anti-TMEFF2-auristatin E conjugated monoclonal antibody; Humanised anti-tomoregulin-auristatin E conjugated mAb; Humanised anti-tomoregulin-auristatin E conjugated monoclonal antibody; huPr1-vcMMAE; PR1-ADC; Pr1-vc-MMAE

Latest Information Update: 12 Mar 2008

Price : $50

At a glance

  • Originator PDL BioPharma
  • Developer Seattle Genetics
  • Class Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Aug 2006 This programme is still in active development
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
  • 22 Jun 2005 Genentech has sublicensed development and commercialisation rights for antibody-drug conjugates directed against the PR1 antigen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top